Temporal Concept – Page 26

Immatics Advances Melanoma T-Cell Therapy into Late-Stage Clinical Trials

11 months ago talkbio0Tagged Immatics, Late stage, melanoma, Phase 3 trial, SUPRAME, T-cell therapy

Immatics, melanoma, T-cell therapy, ACTengine IMA203, late-stage clinical trials, SUPRAME Phase 3 trial

Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment

11 months ago talkbio0Tagged apitegromab, Clinical Trials, GDF8 protein, human, Improvement, Motor function (observable entity), Phase 3, Psychological inhibition, Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition

Siemens Healthineers Secures FDA Approval for Revolutionary 3D Mammography System with 5-Second Acquisition Time

11 months ago talkbio0Tagged 3 Days, Approved, Malignant neoplasm of breast, Mammography, Mammomat B.brilliant, Optical Image Reconstruction, PlatinumTomo, Screening for cancer, Siemens Healthineers, tomosynthesis, UltraHD, United States Food and Drug Administration, wide-angle technology

Siemens Healthineers, FDA approval, 3D mammography, Mammomat B.brilliant, breast cancer screening, wide-angle technology, tomosynthesis, PlatinumTomo, UltraHD image reconstruction.

Johnson & Johnson Halts Phase II Dengue Study Amid Shift in R&D Priorities

11 months ago talkbio0Tagged Antiviral Agents, Communicable Diseases, Dengue Study, Johnson and Johnson, mosnodenvir, Phase II, Priorities, R&D

Johnson & Johnson, Dengue Study, Phase II, Antiviral Drug, Mosnodenvir, Infectious Diseases, R&D Priorities

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

11 months ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

11 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses